TIL therapy

TIL therapy

Oncology An experimental CA therapy in which antigen-
specific tumor-infiltrating T lymphocytes–TILs are isolated from biopsies of Pts with CA and co-administered with IL-2. Cf LAK/IL-2 therapy.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration, the FDA has acknowledged that the ongoing innovaTIL-04 study of TIL therapy LN-145 may be sufficient to support registration in the treatment of patients with advanced cervical cancer.
The 22-day Iovance Gen 2 TIL therapy process is robust and scalable, and has led to impressive responses in melanoma, cervical and head and neck indications, commented Maria Fardis, Ph.D., M.B.A., president and chief executive officer of Iovance.
The general procedure for autologous TIL therapy is stated as follows: (1) the resected melanoma is digested into fragments; (2) each fragment is grown in IL-2 and the lymphocytes proliferate destroying the tumor; (3) after a pure population of lymphocytes exists, these lymphocytes are expanded; and (4) after expansion up to 1011 cells, lymphocytes are infused into the patient (Figure 2(a)) [66].
TIL therapy is being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.
The terminal cancer patients won't benefit directly from the genetic manipulation, but may benefit from the TIL therapy, which can shrink tumors.
Iovance Biotherapeutics announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma.
After TIL therapy, ipilimumab was given to 3 patients who responded: patient 5: PR then SD; patient 7: early PR then progression; and patient 10: SD.
In this role, he was instrumental in driving the company s metastatic melanoma TIL program into clinical development in the first TIL therapy trial performed outside an academic center.
TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center.
Iovance Biotherapeutics announced an update to its clinical programs with TIL therapy in the treatment of cervical cancer and non-small cell lung cancer, or NSCLC.
For a long time, TIL therapy had already shown promise for advanced melanoma patients, with 51% to 72% ORR by Rosenberg et al.
Having exclusivity meaningfully de-risks our development and commercialisation efforts, putting us in an even stronger position to investigate TIL therapy in the treatment of metastatic melanoma.'